Tracking Add-On Diabetes Medicines Used With Insulin in Adults With Type 1 Diabetes
Follows adults with type 1 diabetes taking GLP-1RA or SGLTi medicines alongside insulin.
Plain-language title generated from the registry record
Registry title: Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study
Key facts
- Where
- Atlanta, Boston, Chicago, Cincinnati, Columbus, Detroit, Louisville, Miami, Minneapolis, New York, Newport Beach, Norfolk, Omaha, Portland, Rochester, and San Francisco, United StatesSee the 17 sites
Where in United States
- Emory UniversityAtlanta, United StatesTaking people
- Harvard Medical SchoolBoston, United StatesTaking people
- Northwestern UniversityChicago, United StatesTaking people
- University of CincinnatiCincinnati, United StatesTaking people
- Ohio State UniversityColumbus, United StatesTaking people
- Henry Ford HospitalDetroit, United StatesTaking people
- University of LouisvilleLouisville, United StatesTaking people
- University of MiamiMiami, United StatesTaking people
- HealthPartners, International Diabetes CenterMinneapolis, United StatesTaking people
- Mount SinaiNew York, United StatesTaking people
- NYU Grossman School of MedicineNew York, United StatesTaking people
- Hoag Memorial HospitalNewport Beach, United StatesTaking people
- Eastern Virginia Medical Center, Old Dominion UniversityNorfolk, United StatesTaking people
- University of Nebraska Medical CenterOmaha, United StatesTaking people
- Maine Health Research InstitutePortland, United StatesTaking people
- University of RochesterRochester, United StatesTaking people
- University of California, San Francisco (UCSF)San Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Indiana University
- Trial code
- NCT07676565
- Record updated
- 16 October 2026
- Original description
This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.Read full original descriptionShow less
Safety and Efficacy of Adjunct Therapies in Adults With Type 1diabetes: Multicenter, Registry Study
This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.
Inclusion: Adults ≥18 years of age; Clinical diagnosis of T1D; GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week; Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study; Willing and able to provide informed consent.
Exclusion: No exclusion criteria other than those not meeting inclusion criteria above.